Neurodegenerative Disorder Therapeutics Market Growth Through 2030 Creates New Strategic Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Neurodegenerative Disorder Therapeutics Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for therapeutics targeting neurodegenerative disorders has experienced robust expansion over the past several years. It is projected to rise from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth was driven by factors such as the increasing incidence of neurodegenerative conditions, a growing elderly demographic, insufficient therapeutic alternatives, heightened awareness surrounding early detection, and the ongoing development of hospital and neurology care facilities.
The neurodegenerative disorder therapeutics market is projected to experience robust expansion over the coming years, with an anticipated rise to $34.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.6%. This forecast period growth is driven by several key developments, including the emergence of gene therapies, progress in monoclonal antibody-based treatments, the incorporation of artificial intelligence-powered diagnostic and monitoring tools, increased funding for clinical research and trials, and the broadening of personalized medicine and targeted therapeutics. Among the prominent trends shaping this period are a growing utilization of neuroprotective and neurorestorative therapies, a heightened emphasis on symptom management and patient-centric care, an expansion of clinical trial activities focused on novel neurodegenerative drugs, a further advancement of personalized and targeted therapeutic strategies, and the integration of home care solutions with remote monitoring technologies.
Download A Free Sample Report For Comprehensive Market Insights:
Neurodegenerative Disorder Therapeutics Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated rise in funding directed toward research and development (R&D) for treatments of neurodegenerative disorders is set to fuel expansion within the neurodegenerative disorder therapeutics market moving forward. Such investments are initiated by governments and organizations for several strong reasons, including the growing frequency of these conditions, substantial gaps in existing medical care, associated economic burdens, and worldwide health priorities. As an example, in March 2023, the Government of Canada, a federal entity based in Canada, disclosed a $38.3 million commitment to support research on neurodegenerative diseases. Consequently, this sustained increase in R&D investment for neurodegenerative disorder therapies will keep driving market growth throughout the forecast period.
Neurodegenerative Disorder Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Neurodegenerative Disorder Therapeutics Market Trends: What Is Shaping Future Industry Growth?
Key players in the neurodegenerative disorder therapeutics market are placing increased emphasis on creating novel treatment strategies, including prodrug formulations, designed to boost the bioavailability, effectiveness, and safety profile of therapies for Parkinson’s disease. Prodrugs, which are biologically inactive substances that undergo metabolic conversion into their active pharmacological forms within the body, enable a regulated and prolonged release of active pharmaceutical ingredients. A notable example occurred in January 2024, when AbbVie Inc., a biopharmaceutical firm based in the United States, introduced PRODUODOPA (foslevodopa or foscarbidopa) across the European Union for individuals suffering from advanced Parkinson’s disease. This approach uses a soluble prodrug combination to ensure continuous levodopa administration, with the goal of minimizing motor fluctuations and enhancing patients’ overall quality of life. By providing an alternative to conventional intermittent oral dosing and supporting better adherence to treatment, this product launch marks a crucial step forward in the management of advanced Parkinson’s disease.
Neurodegenerative Disorder Therapeutics Market Key Players And Strategic Industry Positioning
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
Access The Complete Neurodegenerative Disorder Therapeutics Market Report:
Neurodegenerative Disorder Therapeutics Market Largest Region By Revenue And Market Share
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
